Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates and working
1.2.1 North America
1.2.2 Europe
1.2.3 Asia Pacific
1.2.4 Latin America
1.2.5 MEA
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Glaucoma treatment industry 360° synopsis, 2017 – 2028
2.1.1 Business trends
2.1.2 Disease type trends
2.1.3 Drug class trends
2.1.4 Distribution channel trends
2.1.5 Regional trends
Chapter 3 Glaucoma Treatment Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Growing prevalence of glaucoma disease worldwide
3.3.1.2 Technological advancements in therapeutic interventions
3.3.1.3 Rising patient pool of geriatric population across the globe
3.3.1.4 Increasing ongoing clinical trials and product launches for glaucoma treatment
3.3.1.5 Increasing awareness initiatives regarding eye care in underdeveloped and developing nations
3.3.2 Industry pitfalls and challenges
3.3.2.1 Side effects associated with the drugs
3.3.2.2 Stringent product approval process
3.4 Growth potential analysis
3.4.1 By disease type
3.4.2 By drug class
3.4.3 By distribution channel
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2021
3.7.1 Competitive matrix analysis, 2021
3.8 PESTEL analysis
Chapter 4 Glaucoma Treatment Market, By Disease Type
4.1 Key segment trends
4.2 Open angle glaucoma
4.2.1 Market size, by region, 2017 – 2028 (USD Million)
4.3 Angle closure glaucoma
4.3.1 Market size, by region, 2017 – 2028 (USD Million)
4.4 Others
4.4.1 Market size, by region, 2017 – 2028 (USD Million)
Chapter 5 Glaucoma Treatment Market, By Drug Class
5.1 Key segment trends
5.2 Prostaglandin analogs
5.2.1 Market size, by region, 2017 – 2028 (USD Million)
5.3 Beta blockers
5.3.1 Market size, by region, 2017 – 2028 (USD Million)
5.4 Adrenergic agonists
5.4.1 Market size, by region, 2017 – 2028 (USD Million)
5.5 Carbonic anhydrase inhibitors
5.5.1 Market size, by region, 2017 – 2028 (USD Million)
5.6 Others
5.6.1 Market size, by region, 2017 – 2028 (USD Million)
Chapter 6 Glaucoma Treatment Market, By Distribution Channel
6.1 Key segment trends
6.2 Hospital pharmacy
6.2.1 Market size, by region, 2017 – 2028 (USD Million)
6.3 Retail pharmacy
6.3.1 Market size, by region, 2017 – 2028 (USD Million)
6.4 Online pharmacy
6.4.1 Market size, by region, 2017 – 2028 (USD Million)
Chapter 7 Glaucoma Treatment Market, By Region
7.1 Key regional trends
7.2 North America
7.2.1 Market size, by country 2017 – 2028 (USD Million)
7.2.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.2.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.2.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.2.5 U.S.
7.2.5.1 Market size, by country 2017 – 2028 (USD Million)
7.2.5.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.2.5.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.2.5.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.2.6 Canada
7.2.6.1 Market size, by country 2017 – 2028 (USD Million)
7.2.6.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.2.6.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.2.6.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.3 Europe
7.3.1 Market size, by country 2017 – 2028 (USD Million)
7.3.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.3.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.3.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.3.5 Germany
7.3.5.1 Market size, by country 2017 – 2028 (USD Million)
7.3.5.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.3.5.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.3.5.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.3.6 UK
7.3.6.1 Market size, by country 2017 – 2028 (USD Million)
7.3.6.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.3.6.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.3.6.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.3.7 France
7.3.7.1 Market size, by country 2017 – 2028 (USD Million)
7.3.7.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.3.7.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.3.7.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.3.8 Italy
7.3.8.1 Market size, by country 2017 – 2028 (USD Million)
7.3.8.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.3.8.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.3.8.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.3.9 Spain
7.3.9.1 Market size, by country 2017 – 2028 (USD Million)
7.3.9.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.3.9.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.3.9.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.4 Asia Pacific
7.4.1 Market size, by country 2017 – 2028 (USD Million)
7.4.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.4.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.4.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.4.5 China
7.4.5.1 Market size, by country 2017 – 2028 (USD Million)
7.4.5.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.4.5.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.4.5.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.4.6 Japan
7.4.6.1 Market size, by country 2017 – 2028 (USD Million)
7.4.6.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.4.6.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.4.6.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.4.7 India
7.4.7.1 Market size, by country 2017 – 2028 (USD Million)
7.4.7.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.4.7.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.4.7.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.4.8 South Korea
7.4.8.1 Market size, by country 2017 – 2028 (USD Million)
7.4.8.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.4.8.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.4.8.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.4.9 Australia
7.4.9.1 Market size, by country 2017 – 2028 (USD Million)
7.4.9.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.4.9.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.4.9.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.5 Latin America
7.5.1 Market size, by country 2017 – 2028 (USD Million)
7.5.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.5.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.5.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.5.5 Brazil
7.5.5.1 Market size, by country 2017 – 2028 (USD Million)
7.5.5.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.5.5.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.5.5.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.5.6 Mexico
7.5.6.1 Market size, by country 2017 – 2028 (USD Million)
7.5.6.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.5.6.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.5.6.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.5.7 Argentina
7.5.7.1 Market size, by country 2017 – 2028 (USD Million)
7.5.7.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.5.7.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.5.7.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.6 Middle East and Africa
7.6.1 Market size, by country 2017 – 2028 (USD Million)
7.6.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.6.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.6.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.6.5 Saudi Arabia
7.6.5.1 Market size, by country 2017 – 2028 (USD Million)
7.6.5.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.6.5.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.6.5.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.6.6 South Africa
7.6.6.1 Market size, by country 2017 – 2028 (USD Million)
7.6.6.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.6.6.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.6.6.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
7.6.7 UAE
7.6.7.1 Market size, by country 2017 – 2028 (USD Million)
7.6.7.2 Market size, by disease type, 2017 – 2028 (USD Million)
7.6.7.3 Market size, by drug class, 2017 – 2028 (USD Million)
7.6.7.4 Market size, by distribution channel, 2017 – 2028 (USD Million)
Chapter 8 Company Profiles
8.1 Competitive dashboard, 2021
8.2 AERIE Pharmaceuticals, Inc.
8.2.1 Business overview
8.2.2 Financial data
8.2.3 Product landscape
8.2.4 Strategic outlook
8.2.5 SWOT analysis
8.3 Cipla Inc.
8.3.1 Business overview
8.3.2 Financial data
8.3.3 Product landscape
8.3.4 Strategic outlook
8.3.5 SWOT analysis
8.4 Akorn operating company LLC
8.4.1 Business overview
8.4.2 Financial data
8.4.3 Product landscape
8.4.4 Strategic outlook
8.4.5 SWOT analysis
8.5 AbbVie
8.5.1 Business overview
8.5.2 Financial data
8.5.3 Product landscape
8.5.4 Strategic outlook
8.5.5 SWOT analysis
8.6 Bausch & Lomb Incorporated
8.6.1 Business overview
8.6.2 Financial data
8.6.3 Product landscape
8.6.4 Strategic outlook
8.6.5 SWOT analysis
8.7 Inotek Pharmaceuticals
8.7.1 Business overview
8.7.2 Financial data
8.7.3 Product landscape
8.7.4 Strategic outlook
8.7.5 SWOT analysis
8.8 Merck & Co., Inc.
8.8.1 Business overview
8.8.2 Financial data
8.8.3 Product landscape
8.8.4 Strategic outlook
8.8.5 SWOT analysis
8.9 Novartis AG
8.9.1 Business overview
8.9.2 Financial data
8.9.3 Product landscape
8.9.4 Strategic outlook
8.9.5 SWOT analysis
8.10 Pfizer Inc.
8.10.1 Business overview
8.10.2 Financial data
8.10.3 Product landscape
8.10.4 Strategic outlook
8.10.5 SWOT analysis
8.11 Santen Pharmaceutical Co., Ltd.
8.11.1 Business overview
8.11.2 Financial data
8.11.3 Product landscape
8.11.4 Strategic outlook
8.11.5 SWOT analysis
8.12 Teva Pharmaceutical Industries Ltd.
8.12.1 Business overview
8.12.2 Financial data
8.12.3 Product landscape
8.12.4 Strategic outlook
8.12.5 SWOT analysis
8.13 Regeneron pharmaceuticals, Inc.
8.13.1 Business overview
8.13.2 Financial data
8.13.3 Product landscape
8.13.4 Strategic outlook
8.13.5 SWOT analysis
